Renalytix (RNLXY) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Renalytix

OTC Markets OTCQB•Healthcare•Health Information Services

$4.15+0.25(0.06%)Market open

Market Cap

$438.64M

P/S

186.5x

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company's products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize its products in connection with the application of artificial intelligence for the diagnosis of kidney disease. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in London, the United Kingdom.

How this company scores

WeakMetricSide Score: 27/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Growth (10/25); weakest: Profitability (3/25).

Profitability3/25

Growth10/25

Balance Sheet & Red Flags8/25

Cash & Earnings Quality6/25

Strengths

Consistent growthImproving margins

Grade capped at D

Negative equity — the balance sheet is insolvent.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 186.5x5y range 186.5x – 9861.6x

P/B · 15266.1x5y range 15266.1x – 15266.1x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 6 of the last 6 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $438.64M

Metrics at a Glance

as of September 2024

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $2.35M
Q. Revenue: $522,000
TTM EBITDA: $-24.52M
TTM Op. Income: $-24.81M
Q. Op. Income: $-4.09M
TTM Net Income: $-28.03M
Q. Net Income: $-4.73M
EPS: $-0.04
Shares Out.: $105.70M

$2.35M in TTM revenue grew from zero YoY, reaching $522,000 last quarter. TTM EBITDA of $-24.52M and TTM operating income of $-24.81M show growth is flowing through to the bottom line. However, net income is negative at $28.03M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 0% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 19.2%
EBITDA Margin: -772.6%
Op. Margin: -784.1%
Net Margin: -905.7%

Op. margin of -784.1% is up 1152.5% YoY — cost efficiency is improving. Net margin at -905.7% and gross margin of 19.2% show how much of each revenue dollar survives to profit. Across the last 6 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 186.5x
P/B Ratio: N/A

P/S of 186.5x and P/B of 0.0x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $4.79M
Cash: $909,000
Long-Term Debt: $4.10M
Book Value: $-11.32M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-3.84M
TTM Free Cash Flow: $-24.45M
FCF Margin: -1039.4%
FCF / Net Income: 0.9

TTM FCF of $-24.45M on $-3.84M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Across the last 6 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.